Company intelligence / Profile preview

S2 Biosciences

Bristol, Tennessee, United States

Ownership: Private
Development stage: Other

Overview

S2 Biosciences (also known as S2 Therapeutics) was a specialty pharmaceutical company based in Bristol, Tennessee, focused on the development and commercialization of treatments for metabolic diseases. The company is best known for holding the exclusive global license to Cycloset (bromocriptine mesylate), the first FDA-approved treatment for type 2 diabetes that targets the body's biological clock to improve glycemic control. In 2010, S2 Biosciences and its partner VeroScience entered into a significant distribution and license agreement with Santarus, granting the latter exclusive U.S. rights to manufacture and market Cycloset. The company's leadership included Charles P. Sutphin as President and CEO.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

VeroScienceSantarus

Beyond the preview

Go deeper on S2 Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S2 Biosciences.

Explore the full profile